Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07072585CT.gov Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T Lymphoblastic Leukemia/Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bortezomib (this asset) | Children's Oncology Group | P3 | B · 60 |
| Prednisone | Children's Oncology Group | P3 | BB |
| Cytarabine | Princess Maxima Center for Pediatric Oncology | P3 | BB |
| Cyclophosphamide | Children's Oncology Group | P3 | BB |
| Etoposide | Children's Cancer Group, China | P3 | BB |
| Venetoclax | Princess Maxima Center for Pediatric Oncology | P2/3 | B |
| Mercaptopurine Anhydrous | Children's Oncology Group | P3 | B |
| Adriamycin | Children's Oncology Group | P2/3 | B |
| Vincristine Sulfate | Children's Oncology Group | P2/3 | B |
+42 more in the T Lymphoblastic Leukemia/Lymphoma cohort
Other indications for Bortezomib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | BBB · 73 |
| Follicular Lymphoma | — | P2 | BB · 71 |
| Waldenstrom Macroglobulinemia | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bortezomib in T Lymphoblastic Leukemia/Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bortezomib-t-lymphoblastic-leukemialymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →